Last reviewed 2026-04-23 · How we verify

Assigned pulmonary hypertension medication

This drug works by inhibiting the action of endothelin-1, a potent vasoconstrictor.

This drug works by inhibiting the action of endothelin-1, a potent vasoconstrictor. Used for Treatment of pulmonary arterial hypertension.

At a glance

Mechanism of action

Endothelin-1 is a peptide that causes blood vessels to constrict, leading to increased blood pressure. By inhibiting endothelin-1, this drug helps to relax blood vessels and reduce blood pressure.

Approved indications

• Treatment of pulmonary arterial hypertension

Common side effects

• Headache
• Dizziness
• Nausea

Key clinical trials

• A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) (PHASE3)
• Preliminary Human Trials of F230 Tablets (PHASE1)
• Impact of Multi-component Interventions on Populations With Mental Health Symptoms and High-risk COPD (NA)
• Safety, Tolerability and Pharmacokinetics Study of L608 in Healthy Adults (PHASE1)
• The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension
• Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension (PHASE2)
• Study on the Treatment of Nonthrombotic Obstructive Pulmonary Hypertension (NA)
• Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004 (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Assigned pulmonary hypertension medication CI brief — competitive landscape report
• Assigned pulmonary hypertension medication updates RSS · CI watch RSS
• Bayer portfolio CI